You are here: Home: Audio Program Guide: BCU 5 | 2006 Audio: BCU 5 | 2006
 
  Go to Case Discussion: David Dresdner, MD
Go to interview with Julie R Gralow, MD
Go to interview with Edith A Perez, MD
Go to interview with Daniel F Hayes, MD
Go to the Miami Breast Cancer Conference Tumor Panel
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
  Case Discussion: David Dresdner, MD
  
  Click here to download the entire case discussion  
Track 1 Introduction
Track 2 A 60-year-old woman with cardiomyopathy following adjuvant chemotherapy
     
Gralow Julie R Gralow, MD
Associate Professor
Medical Oncology
University of Washington
and Fred Hutchinson Cancer
Research Center
Seattle, Washington		  
  Click here to download the entire interview  
Track 1 Cardiomyopathy associated with anthracycline-based chemotherapy
Track 2 Selection of an adjuvant chemotherapeutic regimen
Track 3 CALGB-49907: AC or CMF versus capecitabine for elderly patients
Track 4 Potential psychosocial benefits of adjuvant capecitabine
Track 5 Current barriers to completing clinical trials
Track 6 Efficacy and tolerability of docetaxel/cyclophosphamide (TC) versus AC

Track 7 Incidence of bone loss among patients with normal bone density in the ATAC trial
Track 8 Selection of up-front adjuvant hormonal therapy
Track 9 Monitoring and managing bone loss in patients on adjuvant aromatase inhibitors
Track 10 Risk of fracture associated with aromatase inhibitors for patients with normal bone density
Track 11 Tolerability and safety of aromatase inhibitors versus tamoxifen
Track 12 Efficacy and tolerability of lapatinib
Track 13 Future directions in lapatinib clinical use and research
Track 14 Time course for initiating therapy with letrozole following five years of adjuvant tamoxifen
Track 15 Duration of adjuvant therapy with an aromatase inhibitor
Track 16 Importance of genomic profiling in the future of breast cancer management
     
Edith A Perez, MD
Professor of Medicine
Mayo Medical School
Director, Cancer Clinical Study Unit
Director, Breast Cancer Program
Division of Hematology and Oncology, Mayo Clinic
Jacksonville, Florida		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Impact of adjuvant trastuzumab data on breast cancer management
Track 3 Importance of waiting for definitive clinical trial data before using an untested therapy
Track 4 Rationale for combined analysis of NCCTG-N9831 and NSABP-B-31 adjuvant trastuzumab trials
Track 5 Design and results of NSABP-B-31 and NCCTGN9831
Track 6 Incidence of brain metastases in trials of adjuvant trastuzumab

Track 7 Similarities and differences between the HERA trial and the combined NSABP/NCCTG analysis
Track 8 Benefit of concurrent versus sequential administration of chemotherapy and trastuzumab observed in
NCCTG-N9831
Track 9 BCIRG 006: Adjuvant trastuzumab with a nonanthracycline-containing regimen
Track 10 Schedule of adjuvant trastuzumab following initial chemotherapy
Track 11 Incidence of false-positive HER2 results with FISH testing
Track 12 Potential correlation between cMYC overexpression and response to trastuzumab
Track 13 Differences in eligibility criteria and definition of cardiac events among adjuvant trastuzumab trials
Track 14 Incidence of cardiac toxicity with adjuvant chemotherapy and trastuzumab
Track 15 Clinical use of adjuvant docetaxel/carboplatin/trastuzumab (TCH)
Track 16 Dose-dense ACArrowpaclitaxel in combination with adjuvant trastuzumab
Track 17 Delayed adjuvant trastuzumab
Track 18 Current role of adjuvant trastuzumab monotherapy
Track 19 Adjuvant trastuzumab for patients with node-negative disease
Track 20 Future NCCTG adjuvant trial for patients with HER2-positive disease
Track 21 Potential benefit of combining lapatinib and trastuzumab
Track 22 Role of trastuzumab in the management of ER-positive, HER2-positive disease
     
Hayes Daniel F Hayes, MD
Professor of Internal Medicine
Clinical Director
Breast Oncology Program
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Adjuvant chemotherapy for older patients
Track 3 Benefit of adjuvant chemotherapy for patients with ER-positive disease
Track 4 Potential biologic rationale for higher response rate to adjuvant chemotherapy in ER-negative versus ER-positive disease
Track 5 Selection of an adjuvant chemotherapeutic regimen for patients with ER-positive, node-positive disease
Track 6 Potential role of capecitabine in the adjuvant setting

Track 7 Cardiac toxicity associated with AC
Track 8 Clinical use of dose-dense AC in the adjuvant setting
Track 9 Development of the Oncotype DX™ assay
Track 10 ECOG-PACCT-1: Adjuvant hormonal therapy with or without chemotherapy based on the Oncotype DX recurrence score
Track 11 Utility of Oncotype DX for patients with HER2-positive disease
Track 12 Reliability of recurrence score in predicting benefit of adjuvant chemotherapy
Track 13 Case discussion: A 51-year-old perimenopausal woman with ER-positive, PR-positive, node-negative disease
Track 14 Regaining ovarian function following chemotherapy-induced or biological amenorrhea
Track 15 Importance of monitoring estradiol in perimenopausal patients receiving adjuvant aromatase inhibitors
Track 16 Use of circulating tumor cells to predict outcome
Track 17 Potential benefit of switching therapies early based on presence of circulating tumor cells
Track 18 Future directions in the assessment of circulating tumor and endothelial cells
     
  Miami Breast Cancer Conference Tumor Panel:
Monoclonal Antibodies in the Management of Early and Advanced Breast Cancer		  
  Click here to download the entire case discussion  
Track 1 Introduction
Track 2 Case discussion: A 46-year-old woman with ER-negative, PR-negative, HER2-negative metastatic disease to the mediastinum and chest wall
Track 3 Case discussion: A 51-year-old woman with ER-positive, HER2-negative metastatic disease to the liver
Track 4 Counseling patients with metastatic breast cancer
Track 5 Strategies to cope with metastatic disease
Track 6 Selection of first-line therapy for patients with triple-negative metastatic disease

Track 7 Side effects and tolerability of bevacizumab
Track 8 Bevacizumab with paclitaxel as first-line therapy for metastatic disease
Track 9 Combination versus sequential single-agent chemotherapy
Track 10 First-line therapy for patients with ER-positive metastatic disease
Track 11 Use of capecitabine in the management of metastatic breast cancer
Track 12 Clinical use of bevacizumab in combination with other chemotherapeutic agents
Track 13 Case discussion: A 33-year-old woman with a 1.7-cm, ER-positive, PR-positive, HER2-positive, node-negative tumor
Track 14 Case discussion: A 44-year-old woman with a 0.8-cm, ER-positive, PR-positive, HER2-positive, node-negative tumor
Track 15 Quality control with HER2 testing
Track 16 Selection of adjuvant therapy for premenopausal women with ER-positive, HER2-positive, node-negative disease
Track 17 Cardiac toxicity with adjuvant trastuzumab
Track 18 Cardiac monitoring for patients receiving adjuvant trastuzumab
Track 19 Adjuvant trastuzumab with chemotherapy for patients with node-negative disease